Quoin Pharmaceuticals, Ltd. (QNRX) News
Track canonical SquawkNews coverage tagged to QNRX, Quoin Pharmaceuticals, Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Quoin Pharmaceuticals Says US FDA Clears Phase 2 Trial of QRX003 in Peeling Skin Syndrome
() -- Quoin Pharmaceuticals (QNRX) said Thursday the US Food and Drug Administration has cleared its planned phase 2 clinical trial of QRX003 to potentially treat peeling skin syndrome. The company said it expects to ini
REGULATION | Jul 09, 2026, 01:42 PM UTC
L
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
EQUITY | Jul 09, 2026, 01:13 PM UTC
L
Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX ) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the United States Patent and Tradema
EQUITY | Jun 30, 2026, 12:31 PM UTC
H
Small Caps Surge
Several small cap stocks are experiencing significant gains premarket due to various positive news announcements, including strategic partnerships and favorable trial data.
EQUITY | Jun 24, 2026, 12:21 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's pre-market session, with Pulsenmore and Catheter Precision leading the gainers and Nuwellis and Mobile-health Network leading the losers
EQUITY | Jun 24, 2026, 12:09 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
H
QNRX Receives FDA Approval
Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome
EQUITY | Jun 23, 2026, 12:30 PM UTC